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Chapel Hill, North Carolina, USAIntroduction: Acute kidney injury (AKI) is a major cause of mortality worldwide, particularly in low-
resource settings with limited diagnostic testing. Neutrophil gelatinase-associated lipocalin (NGAL) has
shown promise in predicting AKI. Nested within a larger, prospective cohort study evaluating AKI inci-
dence in admitted trauma patients, our objective was to evaluate a novel dipstick, NGALds, for the pre-
diction of AKI in Malawi, Africa.
Methods: Participants were >6 months of age. Spearman rank correlation coefficients (R) assessed NGAL
categories (negative [#50 ng/ml], low risk [51149 ng/ml], moderate risk [150299 ng/ml], and high risk
[$300 ng/ml]) for the urine NGALds dipstick and laboratory-based NGAL Test.
Results: We enrolled 285 participants (one-third children). Thirteen percent developed AKI. The dipstick
captured 45 of 52 participants (86.5%) with moderate- or high-risk NGAL values on laboratory-based testing
(R ¼ 0.74). The dipstick had sensitivity of 44.4%, specificity of 73.5%, positive predictive value of 19.5%, and
negative predictive value of 90.2% for predicting AKI. Acute kidney injury was associated with an increased
risk of mortality (relative risk [RR] ¼ 3.9, 95% confidence interval [CI] ¼ 1.98.2), but mortality risk greatly
increased among children who first had a positive ($150 ng/ml) NGALds result (RR¼ 12.0, 95% CI¼ 1.878.4).
Conclusions: The NGALds dipstick performed similarly to the NGAL Test in this low-resource setting and
may be a useful tool to rule out AKI. It may be even more important in predicting high mortality risk among
children.
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ub-Saharan African countries have been excluded
from large surveillance studies of AKI.1,2 Difficulties
with laboratory confirmation of AKI likely contribute to
the paucity of studies on AKI in low-resource areas. The
only diagnostic test for AKI (serum creatinine) continues
to rely on laboratory infrastructure, which remains
limited or nonexistent in low-resource settings.
Currently, the only alternative, low-cost method for
“diagnosing” AKI in such settings is anuria.spondence: Erica C. Bjornstad, 1600 7th Avenue South,
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International Reports (2020) 5, 1791–1798Extensive research has focused on discovery and
validation of novel biomarkers for early detection of
AKI, yet these biomarkers will do little to change the
landscape of AKI recognition in low-resource settings if
they cannot be adapted for areas with inadequate lab-
oratory facilities. Urine NGAL is one such biomarker to
consistently predict subsequent AKI diagnosis in both
adults and children.3–9 Clinical research has shown the
utility of real-time trending of urine NGAL to predict
and to manage AKI, thereby improving patient care.3
In addition, a novel, point-of-care dipstick for urine
NGAL (NGALds; Bioporto, Hellerup, Denmark) was
recently developed. If it proves equally efficacious as
the laboratory urine NGAL, it could be quite promising
for improving AKI diagnostics in low-resource areas.1791
CLINICAL RESEARCH EC Bjornstad et al.: Validity of NGAL Dipstick for Acute Kidney InjuryMalawi, a landlocked country in southeastern Af-
rica, is regularly classified as 1 of the 5 poorest coun-
tries in the world (based on gross domestic product per
capita).10 There are 2 large, central teaching hospitals in
the country that provide the only nephrology care for a
population of 18.6 million.11 Their laboratory services
frequently experience shortages of reagents and power
outages, limiting services at times quite severely. A
novel diagnostic test for AKI that does not rely on re-
agents, electricity, or experienced laboratory techni-
cians could be invaluable in this setting.
Nested within a larger prospective cohort study of
trauma patients in Malawi, we aimed to validate the
urine NGAL biomarker and new NGALds dipstick in a
low-resource environment. We assessed both the
laboratory-based NGALtest (NGAL Test) and the
NGALds dipstick test characteristics for diagnosing
AKI, as defined by creatinine-only Kidney Disease:
Improving Global Outcomes (KDIGO) criteria.12
METHODS
Study Design
This validation study of diagnostic accuracy was nes-
ted within a prospective cohort study to evaluate the
incidence of AKI among admitted trauma patients.13
The study was conducted at Kamuzu Central Hospital
(KCH) in Lilongwe, Malawi.
Study Population
The larger prospective cohort study included all
admitted acute trauma patients at KCH (convenience
sampling). The overall study inclusion criteria were
age $6 months, weight >3 kg, and an expected
admission >24 hours. Both the patient (if $7 years)
and caregiver had to provide written informed con-
sent/assent. Participants were excluded if trauma
occurred >5 days before hospital arrival and if primary
language was not English or Chichewa (the Malawian
official and national languages, respectively). Enroll-
ment (consent and laboratory diagnostics) had to occur
within 18 hours of hospital arrival. The overall study
screened 4547 patients (674 eligible) and enrolled 337
participants.13 For this nested validation study, an
additional requirement for inclusion was the ability to
provide a fresh urine sample on admission.
Outcome
The primary outcome of interest was the validity of the
urine NGALds dipstick as compared to the urine NGAL
laboratory test (NGAL Test) and the gold-standard AKI
diagnosis as defined by creatinine-only KDIGO criteria.12
Serum creatinine, urine laboratory-based NGAL, and
urine NGALds dipstick results were obtained simulta-
neously within 18 hours of arrival. A second serum1792creatinine value was obtained within 48 to 72 hours of
admission. In Malawi, it is not routine for renal function
tests or electrolytes to be obtained on any trauma pa-
tients. To maximize our accuracy for AKI by KDIGO, we
chose to obtain 2 values 48 hours or more apart. Medical
teams could obtain more laboratory tests as they deemed
medically necessary. No participants had a baseline
creatinine value prior to admission. For adult partici-
pants, we assumed a priori a baseline estimated
glomerular filtration rate (eGFR) of 75 ml/min per 1.73
m2 and back-calculated a baseline creatinine using the
Modification of Diet in Renal Disease (MDRD) Study
equation, per KDIGO guidelines,12 and excluding the
race variable as is preferred in African populations.14–17
For pediatric participants, we assumed a priori a baseline
eGFR of 120 ml/min per 1.73 m2 based on previous
literature.18 We subsequently back-calculated a baseline
creatinine using the new (bedside) Schwartz equation
based on our previous work in Malawian children.13,19
As mentioned above, routine laboratory testing is
quite unreliable at KCH’s main public laboratory. To
ensure reliable and consistent laboratory results, all
laboratory testing was conducted at the University of
North Carolina (UNC) Project Malawi Laboratory, which
is a state-of-the-art research laboratory on-site at KCH.
This laboratory maintains a constant supply of reagents,
quality control and assurance measurements, and back-
up generators to ensure high-quality laboratory perfor-
mance for multiple research projects. Creatinine values
were obtained on fresh serum using the Jaffe method on
Roche analyzer Cobas C311 (Basel, Switzerland). Urine
laboratory-based NGAL tests were obtained on fresh
urine samples using the same analyzer with daily control
standards checked. The urine laboratory-based NGAL
(NGAL Test) was reported as a continuous value in
nanograms per milliliter (ng/ml). The novel urine
NGALds dipstick was conducted at the bedside by
trained study nurses who did not have prior knowledge
of the laboratory-based NGAL and creatinine test re-
sults. On a fresh urine sample, 0.1 ml of urine was
pipetted into a pre-prepared, freeze-dried reagent test
tube. Buffer was added for 5 minutes. The dipstick was
inserted and, after 10 minutes, if the control line was
positive, the NGALds dipstick was compared to color-
categorized NGAL values (0 if no color appeared, 25,
50, 100, 150, 300, and 600 ng/ml) for the closest com-
parison (Figure 1).
No adverse events were attributed to obtaining
noninvasive urine specimens for the laboratory-based
and dipstick NGALds tests.
Covariates
To determine whether the novel dipstick performed
differently from other potential variables that may beKidney International Reports (2020) 5, 1791–1798
Figure 1. Neutrophil gelatinase-associated lipocalin (NGALds)
dipstick color category reference.
EC Bjornstad et al.: Validity of NGAL Dipstick for Acute Kidney Injury CLINICAL RESEARCHmore readily available in resource limited settings,
we compared 2 other “tests” to the gold-standard
AKI diagnosis. The participant or caregiver’s self-
report of urine output was assessed on arrival; it
was categorized as decreased or absent versus no
change. In addition, a standard urine dipstick for
assessing proteinuria was assessed on arrival and
classified as negative/trace, 1þ (0.3 g/l), 2þ (1.0 g/l),
3þ (3.0 g/l), or 4þ ($20 g/l).
Additional covariates obtained included gender, age
(in years), mechanism of trauma, body location of
injury, and laboratory-confirmed comorbidities (ane-
mia, sickle cell disease, malaria).20 In addition, we
assessed each participant’s final hospital outcome (dis-
charged home, died, or left against medical advice) and
length of hospitalization.
Sample Size
The overall study aimed to enroll a total of 480
trauma patients (50% children #18 years of age)
who were admitted to KCH to optimally estimateKidney International Reports (2020) 5, 1791–1798the incidence of AKI in trauma patients. This nes-
ted study used all available trauma participants in
the overall study who met inclusion/exclusion
criteria.Analysis
We assessed demographic and injury-related charac-
teristics with descriptive statistics. Spearman rank
correlation coefficients (R) assessed categorical groups
of NGAL values for the urine NGALds dipstick and
laboratory-based NGAL test. Categories included
negative (#50 ng/ml), low risk (51149 ng/ml), mod-
erate risk (150299 ng/ml), and high risk ($300 ng/
ml). We used sensitivity, specificity, positive predic-
tive value (PPV), and negative predictive value (NPV)
to evaluate the validity of the urine NGAL Test
(quantitative laboratory-based values) and urine
NGALds dipstick (categorical values) to diagnose AKI.
Subanalyses were conducted to assess whether the
dipstick performed differently by age or gender. In
addition, self-report of urine output and proteinuria by
urine dipstick were individually compared to the gold-
standard AKI by creatinine-only KDIGO criteria.
Data were double-entered into REDCap electronic
data capture tools hosted at UNC.21 All statistical ana-
lyses were conducted in SAS, version 9.4 (SAS Insti-
tute, Inc., Cary, NC). The institutional review boards at
UNC and Malawi’s National Health Science Research
Committee approved this study.RESULTS
Of the 337 participants enrolled in the overall study,
285 (84.6%) had fresh urinary data on admission
available for analysis. In all, 31.9% (n ¼ 91) of eligible
participants were children (Table 1). Trauma-related
AKI was significantly associated with higher mortal-
ity risk compared to absence of AKI (22.2% vs. 5.6%,
P < 0.001). No patient reported a history of chronic
kidney disease or prior dialysis.Dipstick Versus Laboratory-Based NGAL
The NGALds dipstick categories correlated with
laboratory-based NGAL test results (R ¼ 0.74) on
admission (Table 2). The dipstick captured 45 of 52
participants (86.5%) with moderate- or high-risk lab-
oratory-based NGAL values. The plot presented in
Figure 2 shows that, on average, the laboratory-based
NGAL results matched the NGALds dipstick category
(e.g., for all individuals with a dipstick result of 150,
average laboratory-based NGAL result of 127.5). Sub-
group analyses revealed similar results for adults and
children.1793
Table 2. Categorical comparisons of urine NGAL values on admission













Negative (#50) 128 26 2 0 0.74
Low risk
(51149)
13 17 2 3
Moderate risk
(150299)
4 15 4 1
High risk
($300)
2 8 18 22
NGA, neutrophil gelatinase-associated lipocalin.
aTwenty participants were missing laboratory-based test results.
Table 1. Demographics of hospitalized malawian trauma patients by
development of acute kidney injury
Demographic factors
Total AKI No AKI
Missing data
N [ 285 36 (12.6) 249 (87.4)
Age, yr, median (IQR) 25 (13, 38) 30 (19,41) 25 (13,38) 2
Children #18 yr 91 (31.9) 9 (25.0) 82 (32.9) 2
Gender (male) 225 (78.9) 30 (83.3) 195 (78.3) 1
Type/location of trauma
Burns 32 (11.2) 8 (22.2) 24 (9.6) 5
Motor vehicle related 123 (43.2) 16 (44.4) 107 (43.0) 5
Assaults 53 (18.6) 6 (16.7) 47 (18.9) 5
Truncal injury 80 (28.1) 15 (41.7) 65 (26.1) 2
Multiple injuries 149 (52.3) 24 (66.7) 125 (50.2) 2
Comorbidities
Anemia 137 (48.1) 23 (63.9) 114 (45.8) 0
Malaria 22 (7.7) 1 (2.8) 21 (8.4) 4
Sickle cell traita 20 (7.0) 3 (8.3) 17 (6.8) 15
Length of stay,b days,
median (IQR)
11 (6, 28) 13 (8, 46) 11 (6, 27) 15c
Mortality 22 (7.7) 8 (22.2) 14 (5.6) 12d
AKI, acute kidney injury; IQR, interquartile range.
aNo patients had sickle cell disease (HgSS), so only sickle cell trait (HgAS) is presented.
bLength of stay is for those patients discharged alive (n ¼ 250).
cSix patients left against medical advice, 6 had lost files, and 3 discharge dates could
not be confirmed.
dSix patients left against medical advice and 6 had lost files.
All data are presented as n (%) unless otherwise specified.
CLINICAL RESEARCH EC Bjornstad et al.: Validity of NGAL Dipstick for Acute Kidney InjuryValidity of NGAL to Diagnose AKI
In all, 273 participants had both urine samples for
dipstick testing and hospital outcome data (mortality)
available, and 12.5% developed AKI. Figure 3 dem-
onstrates that if we screened all trauma participants
with dipsticks, subsequently tested creatinine for AKI
confirmation among only those with positive dipsticks
($150 ng/ml), then the dipstick would have captured
44% of AKI episodes (15 of 34). However, we would
also drastically reduce the number that we screened
with creatinine tests from 273 down to 78, an almost
75% reduction in testing. In addition, the NGALds
dipstick was elevated ($150 ng/ml) in 10 of 22 par-
ticipants who died (45%). Table 3 provides the test
characteristics of NGALds dipstick on admission urine
samples compared to creatinine-only KDIGO-defined
AKI diagnosis. Based on a threshold of 150 ng/ml, the
dipstick had moderate specificity (73.5%) but poor
sensitivity (44.4%). Subgroup analyses revealed
consistent results in adults and children. However,
among children, a threshold of 150 ng/ml had higher
specificity (84.2%), with sensitivity of 22.2% for
detecting AKI. Further analyses to assess the dipstick
versus different stages of AKI were limited by the
sample size. Only 12 patients had severe (stage 2 or 3)
AKI. There was a strong association with a low
NGALds dipstick level (<150 ng/ml) and no AKI (P <
0.0001). No association was found between dipstick
result and individual AKI stages. A receiver operating1794characteristic (ROC) curve is provided in
Supplementary Figure S1. The laboratory-based NGAL
test performed similarly to the dipstick test for char-
acterizing AKI (Supplementary Table S1).
Validity of Proteinuria and Anuria to Diagnose
AKI
The presence of proteinuria ($0.3g/l) revealed test
characteristics similar to those of NGAL for diagnosing
AKI (sensitivity 46.0%, specificity 79.6%, PPV 24.6%,
NPV 91.0%). As expected, higher proteinuria was
linked to higher specificity, but sensitivity declined
precipitously to <3% at $3.0 g/l. Proteinuria was
present among 30% of participants who died, which is
lower than the 45% captured by NGALds. A report of
decreased or absent urine output was a very poor in-
dicator for AKI (sensitivity 16.1%, specificity 86.4%)
and was not available for 20.5% of participants.
Mortality
In our population, participants who developed AKI had
4 times higher mortality risk than those who did not
develop AKI (RR ¼ 4.0, 95% CI ¼ 1.88.8) (Figure 4).
When stratified by age, children had a slightly higher
risk (RR ¼ 6.6, 95% CI ¼ 1.333.8). However, chil-
dren with an elevated NGAL dipstick ($150 ng/ml)
who developed AKI had the highest mortality risk
(RR ¼ 12.0, 95% CI ¼ 1.878.4). There were no dif-
ferences by gender.
DISCUSSION
We present one of the first validation studies of the
novel NGALds dipstick for AKI diagnosis. We found
evidence to support the use of this point-of-care test to
rule out AKI in trauma patients, particularly in low-
resource settings. Moreover, children with an
elevated dipstick level and AKI had an extremely high
mortality rate, suggesting that this test may be useful
for risk stratification of pediatric patients.
The dipstick was a useful tool to rule out AKI
(specificity 73.5%, NPV 90.2%). For a diagnostic test, aKidney International Reports (2020) 5, 1791–1798
Figure 2. Laboratory-based neutrophil gelatinase-associated lipocalin (NGAL) results by NGALds dipstick categories. Twenty participants were
missing laboratory-based NGAL values on admission. Individual points are depicted, with common thresholds indicated by the horizontal lines
(at 150 ng/ml and 300 ng/ml). Actual NGALds dipstick results indicated below the plot with the corresponding average test result of the
laboratory-based NGAL values for all individuals within the dipstick category.
EC Bjornstad et al.: Validity of NGAL Dipstick for Acute Kidney Injury CLINICAL RESEARCHhigh specificity to rule out disease is prioritized over
sensitivity, which helps to rule in disease. In a country
that currently uses subjective clinical signs on a
routine basis for AKI diagnosis, determining which











Survived without AKI, NGALds –
Figure 3. Admitted Malawian trauma patients screened with
NGALds dipstick and interplay of positive dipstick, AKI, and mortality.
Total screened participants with outcome data, n ¼ 273; participants
with NGALdsþ, n ¼ 78; participants with AKI, n ¼ 34; participants
who died, n ¼ 22; participants who survived without AKI and had
NGALds results, n ¼ 167. AKI, acute kidney injury. NGALdsþ refers
to NGALds dipstick results $150 ng/ml. NGALds refers to NGALds
dipstick results <150 ng/ml.
Kidney International Reports (2020) 5, 1791–1798this stage, potentially more important than AKI
confirmation. We do not believe that the NGALds
dipstick will replace a serum creatinine test, but in an
impoverished area, the dipstick might be a useful triage
tool for district or rural hospitals that have no creati-
nine testing, as an objective marker to prioritize limited
transportation for the sickest of patients. In addition,
the dipstick could be incorporated into clinical algo-
rithms for subsequent creatinine testing as a more cost-
effective screening tool for AKI. Current estimates are
for the test to be sold at $0.50 to $1 USD (85%93%
less expensive than the cost of serum creatinine,
w$6.80 USD per test).Table 3. Urine NGALds Dipstick Test Predictive Characteristics
Using KDIGO-defined AKI (creatinine-onlya) in Malawian Trauma
Patients
Urine NGALds Dipstick category Sensitivity Specificity PPV NPV
25 97.2 3.6 12.7 90.0
50 61.1 47.0 14.3 89.3
100 58.3 61.0 17.8 91.0
150 44.4 73.5 19.5 90.2
300 36.1 82.7 23.2 90.0
AKI, acute kidney injury; KDIGO, Kidney Disease: Improving Global Outcomes; NGAL,
neutrophil gelatinase-associated lipocalin; NPV, negative predictive value; PPV, positive
predictive value.
aUsing admission urine samples only (n ¼ 285).
1795
Overall NGAL Dipsck + NGAL Dipsck –
ALL parcipants 4.0 4.2 3.1
Adults 3.3 2.9 3.6










































Figure 4. Relative risk of mortality for Malawian trauma patients with acute kidney injury stratified by age and NGALds dipstick results. The
figure presents the relative risk (RR) of mortality for those with and without AKI (n ¼ 12 missing outcome data). Left section presents the RR of
mortality among all participants (further stratified by age). Middle section presents the RR of mortality among only those individuals with first a
positive NGAL dipstick on admission (further stratified by age). Right section presents the RR of mortality among only those individuals with first
a negative NGAL dipstick on admission (further stratified by age). Actual RR is presented at the bottom, with 95% confidence interval in pa-
rentheses. AKI, acute kidney injury; NGAL, neutrophil gelatinase-associated lipocalin; Dipstickþ, positive NGALds dipstick ($150 ng/ml);
Dipstick , negative NGALds dipstick (<150 ng/ml).
CLINICAL RESEARCH EC Bjornstad et al.: Validity of NGAL Dipstick for Acute Kidney InjuryThe dipstick seems to be more promising for pre-
dicting mortality after subsequent AKI diagnosis,
particularly in children (RR ¼ 12.0, 95% CI ¼
1.878.4) compared to adults (RR ¼ 2.9, 95% CI ¼
0.711.6). This result is consistent with findings that
laboratory-based NGAL is a better predictor of AKI in
children compared to adults.22
Currently, the only point-of-care AKI diagnostic
tests available clinically are expensive and require
temperature-controlled units.23,24 We demonstrated
that it was logistically feasible for clinical staff in a
low-resource area to obtain urine (collected in >84%
on admission, >90% overall) and to use a novel
point-of-care dipstick. In addition, the dipstick has a
shelf life at room temperature of >1 month. Given
the limited laboratory infrastructure and unreliability
of testing, clinicians in Malawi and many other low-
resource areas often wait until a patient is anuric for
24þ hours before diagnosing AKI. This is often too
late for preventive and management strategies to
effectively change the AKI course and to prevent the
need for dialysis, which is often a “death sentence”
in areas with limited access to dialysis care. A robust
point-of-care test could expand AKI screening/risk1796stratification to remote areas at district hospitals and
health centers, expediting transfer of the most at-risk
trauma patients.
This study has several limitations. Given resource
limitations and costs, we were only able to obtain at
most two creatinine values. Most AKI studies tend to
obtain 4 to 7 daily creatinine values, so it is possible
that we underdiagnosed AKI events. In addition, there
is no standard consensus for defining baseline creati-
nine among children. We previously showed that the
baseline creatinine definition for children has a strong
impact on detected AKI incidence and that for this
African setting, the new Schwartz equation may be
optimal.13 We conducted a prospective study because
retrospective and case-control studies are difficult in
low-resource areas in which creatinine values are not
routinely obtained. However, only 36 participants
developed AKI, and only 12 developed severe AKI
(stage 2 or 3), thereby limiting our inferences. Larger
studies are needed. Our associations of AKI and
NGALds dipstick results with mortality should not be
viewed as causal. We are able to show an association
only with mortality; these may both be indicating
severity of trauma. Further studies should evaluate AKIKidney International Reports (2020) 5, 1791–1798
EC Bjornstad et al.: Validity of NGAL Dipstick for Acute Kidney Injury CLINICAL RESEARCHand point-of-care test results in the context of trauma
severity and other complications (such as sepsis) that
could confound associations with patient mortality.
Previous studies have indicated relationships between
urinary tract infections and chronic kidney disease
with creatinine and NGAL values. Although we did not
assess for UTIs specifically in this study, all patients
presented for trauma, so this should be minimal to
nonexistent. No patients reported a history of chronic
kidney disease, but this could have been missed. There
is limited outpatient care for nephrology in Malawi,
and baseline creatinine values were not known for any
of our patients.
In conclusion, because AKI can be silent and
asymptomatic until it is quite severe, the ability to
detect AKI where reliable, routine laboratory testing is
not available could improve care and outcomes. Our
project is one of the first validation studies of the novel
NGALds dipstick that holds such promise as an AKI
point-of-care test. We showed that in a trauma popu-
lation in Malawi, the dipstick was good at ruling out
AKI, and may be useful for overall risk stratification of
pediatric trauma patients. Further investigations are
needed as the dipstick potentially has other applica-
tions beyond trauma in Malawi: other African
countries, disaster settings, conflict zones, rural areas,
and in the setting of other diseases with a high risk of
AKI.DISCLOSURE
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Table S1. Urine laboratory-based NGAL test predictive
characteristics using KDIGO-defined AKI (creatinine-only*)
in Malawian trauma patients.
Figure S1. ROC curve for NGALds Dipstick on AKI
diagnosis.
STARD Checklist.Kidney International Reports (2020) 5, 1791–1798REFERENCES
1. Susantitaphong P, Cruz DN, Cerda J, et al. World incidence of
AKI: a meta-analysis. Clin J Am Soc Nephrol. 2013;8:1482–
1493.
2. Kaddourah A, Basu RK, Bagshaw SM, Goldstein SL. Epide-
miology of acute kidney injury in critically ill children and
young adults. N Engl J Med. 2017;376:11–20.
3. Varnell CD, Goldstein SL, Devarajan P, Basu RK. Impact of
near real-time urine neutrophil gelatinase–associated lip-
ocalin assessment on clinical practice. Kidney Int Reports.
2017;2:1243–1249.
4. Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-
associated lipocalin (NGAL) as a biomarker for acute renal
injury after cardiac surgery. Lancet. 2005;365:1231–1238.
5. Parikh CR, Coca SG, Thiessen-Philbrook H, et al. Post-
operative biomarkers predict acute kidney injury and poor
outcomes after adult cardiac surgery. J Am Soc Nephrol.
2011;22:1748–1757.
6. Bennett M, Dent CL, Ma Q, et al. Urine NGAL predicts severity
of acute kidney injury after cardiac surgery: a prospective
study. Clin J Am Soc Nephrol. 2008;3:665–673.
7. Zappitelli M, Washburn KK, Arikan AA, et al. Urine neutrophil
gelatinase-associated lipocalin is an early marker of acute
kidney injury in critically ill children: a prospective cohort
study. Crit Care. 2007;11:R84.
8. Nickolas TL, O’Rourke MJ, Yang J, et al. Sensitivity and
specificity of a single emergency department measurement
of urinary neutrophil gelatinase-associated lipocalin for
diagnosing acute kidney injury. Ann Intern Med. 2008;148:
810–819.
9. Makris K, Markou N, Evodia E, et al. Urinary neutrophil
gelatinase-associated lipocalin (NGAL) as an early marker of
acute kidney injury in critically ill multiple trauma patients.
Clin Chem Lab Med. 2009;47:79–82.
10. The World Bank. GDP per capita (current US$). Available at:
https://data.worldbank.org/indicator/ny.gdp.pcap.cd?year_
high_desc¼false. Accessed April 4, 2019.
11. The World Bank. Population, Total. Available at: https://data.
worldbank.org/indicator/sp.pop.totl. Accessed April 4, 2019.
12. Kellum AJ. KDIGO clinical practice guideline for acute kidney
injury. Kidney Int. 2012;2:1–138.
13. Bjornstad EC, Muronya W, Smith ZH, et al. Incidence and
epidemiology of acute kidney injury in a pediatric Malawian
trauma cohort: a prospective observational study. BMC
Nephrol. 2020;21:1–12.
14. Moodley N, Hariparshad S, Peer F, Gounden V. Evaluation of
the CKD-EPI creatinine based glomerular filtration rate esti-
mating equation in Black African and Indian adults in
KwaZulu-Natal, South Africa. Clin Biochem. 2018;59:43–49.
15. Bukabau JB, Sumaili EK, Cavalier E, et al. Performance of
glomerular filtration rate estimation equations in Congolese
healthy adults: the inopportunity of the ethnic correction.
PLoS One. 2018;13:e0193384. https://doi.org/10.1371/journal.
pone.0193384.
16. Madala ND, Nkwanyana N, Dubula T, Naiker IP. Predictive
performance of eGFR equations in South Africans of African
and Indian ancestry compared with 99mTc-DTPA imaging.
Int Urol Nephrol. 2012;44:847–855.1797
CLINICAL RESEARCH EC Bjornstad et al.: Validity of NGAL Dipstick for Acute Kidney Injury17. Van Deventer HE, George JA, Paiker JE, et al. Estimating glomer-
ular filtration rate in black South Africans by use of the modifica-
tion of diet in renal disease and Cockcroft-Gault equations. Clin
Chem. 2008;54:1197–1202.
18. Zappitelli M, Parikh CR, Akcan-Arikan A, et al. Ascertainment
and epidemiology of acute kidney injury varies with definition
interpretation. Clin J Am Soc Nephrol. 2008;3:948–954.
19. Schwartz GJ, Munoz A, Schneider MF, et al. New equations to esti-
mate GFR in children with CKD. J AmSoc Nephrol. 2009;20:629–637.
20. Kobusingye OC, Lett RR. Hospital-based trauma registries in
Uganda. J Trauma. 2000;48:498–502.
21. Harris PA, Taylor R, Thielke R, et al. Research electronic data
capture (REDCap)-A metadata-driven methodology and1798workflow process for providing translational research infor-
matics support. J Biomed Inform. 2009;42:377–381.
22. Haase M, Bellomo R, Devarajan P, et al. Accuracy of
neutrophil gelatinase-associated lipocalin (NGAL) in diag-
nosis and prognosis in acute kidney injury: a systematic
review and meta-analysis. Am J Kidney Dis. 2009;54:1012–
1024.
23. Gibney RTN, Sever MS, Vanholder RC. Disaster
nephrology: crush injury and beyond. Kidney Int. 2014;85:
1049–1057.
24. Tran NK, Godwin Z, Bockhold J, Kost GJ. Point-of-care testing
at the disaster-emergency-critical care interface. Point Care.
2012;11:180–183.Kidney International Reports (2020) 5, 1791–1798
